Pehlivan Melek, Çalışkan Ceyda, Yüce Zeynep, Sercan Hakki Ogun
Vocational School of Health Services, Izmir Katip Celebi University, Izmir, Turkey.
Izmir Institute of Technology, Faculty of Science, Department of Molecular Biology & Genetics, Izmir, Turkey.
Leuk Res. 2018 Jun;69:24-30. doi: 10.1016/j.leukres.2018.03.011. Epub 2018 Mar 28.
Wnt signaling has been a topic of research for many years for its diverse and fundamental functions in physiological (such as embryogenesis, organogenesis, proliferation, tissue repair and cellular differentiation) and pathological (carcinogenesis, congenital/genetic diseases, and tissue degeneration) processes. Wnt signaling pathway aberrations are associated with both solid tumors and hematological malignancies. Unregulated Wnt signaling observed in malignancies may be due to a wide spectrum of abnormalities, from mutations in the genes of key players to epigenetic modifications of Wnt antagonists. Of these, Wnt antagonists are gaining significant attention for their potential of being targets for treatment and inhibition of Wnt signaling. In this review, we discuss and summarize the significance of Wnt signaling antagonists in the pathogenesis and treatment of hematological malignancies.
多年来，Wnt信号传导因其在生理过程（如胚胎发生、器官发生、增殖、组织修复和细胞分化）和病理过程（癌症发生、先天性/遗传性疾病以及组织退化）中具有多样且重要的功能，一直是研究的热点。Wnt信号通路异常与实体瘤和血液系统恶性肿瘤均相关。在恶性肿瘤中观察到的Wnt信号传导失控可能归因于广泛的异常情况，从关键分子基因的突变到Wnt拮抗剂的表观遗传修饰。其中，Wnt拮抗剂因其作为Wnt信号传导治疗和抑制靶点的潜力而备受关注。在本综述中，我们讨论并总结了Wnt信号拮抗剂在血液系统恶性肿瘤发病机制和治疗中的意义。
